Get the Stockscreener App
0.319
4.35%
-0.0145
After Hours:
.34
0.021
+6.58%
Cyclacel Pharmaceuticals Inc stock is traded at $0.319, with a volume of 199.22K.
It is down -4.35% in the last 24 hours and down -14.02% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
See More
Previous Close:
$0.3335
Open:
$0.3201
24h Volume:
199.22K
Relative Volume:
0.09
Market Cap:
$4.44M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.0339
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-8.86%
1M Performance:
-14.02%
6M Performance:
-73.85%
1Y Performance:
-87.96%
1-Day Range:
$0.3106
$0.33
1-Week Range:
$0.3106
$0.3634
52-Week Range:
$0.3014
$4.00
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.319 | 4.44M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News
Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com
(CYCCP) Trading Report - Stock Traders Daily
Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - Investing.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8 million in funding -February 03, 2025 - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Creditors Voluntary Liquidation Of UK Subsidiary - Marketscreener.com
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com - Defense World
(CYCCP) On The My Stocks Page - Stock Traders Daily
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy - MSN
Cyclacel Pharmaceuticals Corrects Inadvertent Error in Securities Purchase Agreement - Defense World
How the (CYCCP) price action is used to our Advantage - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals Announces Agreement for $3.1 Million Investment by David Lazar as Interim CEO - Defense World
Cyclacel Pharmaceuticals Restructures Leadership and Financial Strategy - TipRanks
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - citybiz
Stock market news: Nauticus Robotics gained 93.71% while N2OFF rose by 128.03% during mid day trading - Business Upturn
Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing - Benzinga
Cyclacel Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December - Benzinga
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps - Seeking Alpha
Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring - StockTitan
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Trend Tracker for (CYCCP) - Stock Traders Daily
Cyclacel stock plunges to 52-week low, hits $0.32 - Investing.com India
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Stock Watch: A Biotech Holiday Horror Story - Citeline News & Insights
Cyclacel Pharmaceuticals Faces Potential Delisting from Nasdaq Stock Market Due to Minimum Bid Price Noncompliance - Defense World
Trading (CYCCP) With Integrated Risk Controls - Stock Traders Daily
Cash-strapped Cyclacel cuts costs as it searches for financial lifeline - Fierce Biotech
Cyclacel Pharmaceuticals Exploring Alternatives, Cuts Costs to Preserve Cash - MarketWatch
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - The Manila Times
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):